A diagnostic gene profile for molecular subtyping of breast cancer associated with treatment response
暂无分享,去创建一个
Jason S. Carroll | René Bernards | Oscar Krijgsman | Annuska M. Glas | Paul Roepman | A. Glas | R. Bernards | J. Carroll | W. Zwart | P. Roepman | O. Krijgsman | R. Bender | Wilbert Zwart | S. Tian | Sun Tian | F. Snoo | Femke de Snoo | R. A. Bender
[1] Peter Joosten,et al. Gene expression profiling in follicular lymphoma to assess clinical aggressiveness and to guide the choice of treatment. , 2005, Blood.
[2] Wim H van Harten,et al. Use of 70-gene signature to predict prognosis of patients with node-negative breast cancer: a prospective community-based feasibility study (RASTER). , 2007, The Lancet. Oncology.
[3] G. Hortobagyi,et al. Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[4] Van,et al. A gene-expression signature as a predictor of survival in breast cancer. , 2002, The New England journal of medicine.
[5] Ian O Ellis,et al. Basal-like breast cancer: a critical review. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[6] P. Hall,et al. An expression signature for p53 status in human breast cancer predicts mutation status, transcriptional effects, and patient survival. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[7] R. Tibshirani,et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[8] Anna L. Brown,et al. Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[9] C. Sotiriou,et al. Gene expression profiling in breast cancer. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.
[10] S. Paik,et al. Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[11] Robert N. Stavins,et al. ENVIRONMENTAL REGULATION IN THE 1990 S : A RETROSPECTIVE ANALYSIS , 2003 .
[12] A. Tan,et al. Iniparib, a PARP1 inhibitor for the potential treatment of cancer, including triple-negative breast cancer. , 2010, IDrugs : the investigational drugs journal.
[13] P. Kauraniemi,et al. Activation of multiple cancer-associated genes at the ERBB2 amplicon in breast cancer. , 2006, Endocrine-related cancer.
[14] I. Ellis,et al. Triple-Negative Breast Cancer: Distinguishing between Basal and Nonbasal Subtypes , 2009, Clinical Cancer Research.
[15] M. J. van de Vijver,et al. Microarray-Based Determination of Estrogen Receptor, Progesterone Receptor, and HER2 Receptor Status in Breast Cancer , 2009, Clinical Cancer Research.
[16] R. Gelber,et al. Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2009 , 2009, Annals of oncology : official journal of the European Society for Medical Oncology.
[17] A. Nobel,et al. Supervised risk predictor of breast cancer based on intrinsic subtypes. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[18] Marcin Skrzypski,et al. An Immune Response Enriched 72-Gene Prognostic Profile for Early-Stage Non–Small-Cell Lung Cancer , 2009, Clinical Cancer Research.
[19] E. Liu,et al. An Oestrogen Receptor α-bound Human Chromatin Interactome , 2009, Nature.
[20] Christian A. Rees,et al. Molecular portraits of human breast tumours , 2000, Nature.
[21] Roman Rouzier,et al. Breast Cancer Molecular Subtypes Respond Differently to Preoperative Chemotherapy , 2005, Clinical Cancer Research.
[22] Lajos Pusztai,et al. Molecular classification of breast cancer: limitations and potential. , 2006, The oncologist.
[23] Sarah L Vowler,et al. Cooperative interaction between retinoic acid receptor-alpha and estrogen receptor in breast cancer. , 2010, Genes & development.
[24] E. Berns,et al. Additional value of the 70-gene signature and levels of ER and PR for the prediction of outcome in tamoxifen-treated ER-positive breast cancer. , 2012, Breast.
[25] Daniel Birnbaum,et al. How basal are triple‐negative breast cancers? , 2008, International journal of cancer.
[26] Amy V Kapp,et al. Discovery and validation of breast cancer subtypes , 2006, BMC Genomics.
[27] J. Haerting,et al. Gene-expression signatures in breast cancer. , 2003, The New England journal of medicine.
[28] Discovery and validation of breast cancer subtypes , 2007, BMC Genomics.
[29] Charles M. Perou,et al. Ki67 Index, HER2 Status, and Prognosis of Patients With Luminal B Breast Cancer , 2009, Journal of the National Cancer Institute.
[30] C. Perou,et al. The Triple Negative Paradox: Primary Tumor Chemosensitivity of Breast Cancer Subtypes , 2007, Clinical Cancer Research.
[31] L. Holmberg,et al. Gene expression profiling spares early breast cancer patients from adjuvant therapy: derived and validated in two population-based cohorts , 2005, Breast Cancer Research.
[32] J. Ross,et al. Pharmacogenomic predictor of sensitivity to preoperative chemotherapy with paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide in breast cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[33] A. Ashworth,et al. Breast cancer molecular profiling with single sample predictors: a retrospective analysis. , 2010, The Lancet. Oncology.
[34] Douglas G Altman,et al. Reporting recommendations for tumor marker prognostic studies. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[35] A. Gown,et al. Immunohistochemical and Clinical Characterization of the Basal-Like Subtype of Invasive Breast Carcinoma , 2004, Clinical Cancer Research.
[36] C. Perou,et al. Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma , 2006, Modern Pathology.
[37] Yudong D. He,et al. Gene expression profiling predicts clinical outcome of breast cancer , 2002, Nature.
[38] K. Hess,et al. Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[39] M. Cronin,et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. , 2004, The New England journal of medicine.
[40] Annuska M. Glas,et al. The 70-gene signature as a response predictor for neoadjuvant chemotherapy in breast cancer , 2010, Breast Cancer Research and Treatment.
[41] A. Nobel,et al. Concordance among Gene-Expression – Based Predictors for Breast Cancer , 2011 .
[42] M. F. Parry,et al. A Retrospective Analysis , 1990 .
[43] Amy V Kapp,et al. Are clusters found in one dataset present in another dataset? , 2007, Biostatistics.